Photronics shares rallied as much as 50% on Wednesday, noting the biggest intraday rise since March 2009, after the semiconductor company forecast revenue for the first quarter that beat the average analyst estimate. Photronics is one of the largest semiconductors photomasks producers in the world; photomasks are important part of infrastructure. The EPS came in almost 35% higher than market consensus.
Fiscal Q4 results:
- Adjusted EPS 60c vs. 59c y/y, estimate 45c
- Revenue $215.8 million, -3.1% y/y, estimate $205.3 million
- EPS $1.07 vs. 54c y/y
Fiscal Q1 forecasts:
- Sees revenue $217 million to $225 million, estimate $207.3 million (Bloomberg Consensus)
- Sees adjusted EPS 51c to 59c (estimate 46c)
Source: xStation5
Photronics valuation even after today stock surge remain potentially attractive with PE ratio in mid 20s and 2.5 price to sales ratio. The company net margin is surging, as well as net income which came at almost $62 million, which is almost 35% better result than previous record from Q3 2023.
Source: Bloomberg Finance L.P, XTB Research
Daily summary: SILVER at a new ATH, EURUSD at its highest since October
Stock of the Week โ Jabil Inc (11.12.2025)
Rivian is developing its own AI chip for autonomous driving ๐ก
Disney invests in OpenAI and announces a revolution in animation creation ๐ฑ
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
